Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Treatment Goals in Newly Diagnosed Multiple Myeloma

June 29th 2015

Elotuzumab and Daratumumab in Multiple Myeloma

June 29th 2015

Introduction: Monoclonal Antibodies in Multiple Myeloma

June 29th 2015

Venetoclax Combination Shows Antitumor Activity in Advanced Myeloma

June 20th 2015

A three-drug combination comprising the novel Bcl-2 inhibitor venetoclax, bortezomib, and dexamethasone demonstrated a clinical benefit in heavily pretreated patients with relapsed/refractory multiple myeloma.

Panobinostat PFS Benefit Extended in PANORAMA-1 Subgroup Analysis

June 13th 2015

The addition of panobinostat to bortezomib and dexamethasone improved progression-free survival by 7.8 months in a subgroup of 147 patients with multiple myeloma who had received at least 2 prior treatments, including bortezomib and an immunomodulatory agent.

Treating Newly Diagnosed Multiple Myeloma

June 13th 2015

Maintenance Therapy Improves Outcomes in Multiple Myeloma

June 13th 2015

Maximizing Stem Cell Transplantation in Multiple Myeloma

June 13th 2015

Emerging Combinations for Relapsed/Refractory Multiple Myeloma

June 13th 2015

Monitoring Response and Defining Complete Remission in Multiple Myeloma

June 13th 2015

Dr. Saad Usmani on Daratumumab Monotherapy for Multiple Myeloma

June 11th 2015

Saad Z. Usmani, MD, director, Clinical Research Hematologic Malignancies, director, Plasma Cell Disorders, Levine Cancer Institute/Carolinas Healthcare System, discusses daratumumab for patients with relapsed/refractory multiple myeloma.

Elotuzumab and Daratumumab Shown to Improve Outcomes in Multiple Myeloma

June 9th 2015

Sagar Lonial, MD, discusses the future of monoclonal antibodies in multiple myeloma.

2015 ASCO Annual Meeting Highlights

June 5th 2015

CD19-Targeted CAR T-Cell Therapy Shows Promise in Multiple Myeloma

June 5th 2015

The CD19-targeted chimeric antigen receptor T-cell therapy CTL019 demonstrated early evidence of activity and safety in patients with refractory multiple myeloma.

Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple Myeloma

June 5th 2015

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.

Daratumumab Data Impresses in Myeloma, FDA Submission Expected

May 30th 2015

Daratumumab demonstrated a 65% one-year overall survival rate and a 29.2% objective response rate in patients with double refractory heavily pretreated multiple myeloma.

New Paradigm Emerging in Multiple Myeloma Therapy

May 14th 2015

The emerging treatment landscape for patients with high-risk multiple myeloma is burgeoning with new classes of drugs, novel agents, and fresh combination strategies that offer many promising and exciting options for future therapeutic approaches.

Monoclonal Antibody-Directed Therapies for the Management of Multiple Myeloma

May 11th 2015

Several monoclonal antibodies with multiple myeloma cell antigen or bone marrow targets have exhibited strong antimyeloma activity and may become potential therapeutic agents.

Dr. Kenneth Anderson on Combining Immunotherapies in Myeloma

May 6th 2015

Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

FDA Updates Pomalidomide Multiple Myeloma Label

April 24th 2015

The FDA has updated the label for pomalidomide plus low-dose dexamethasone for multiple myeloma to include data from the phase III MM-003 study.

x